OBJECTIVE: To estimate trends in the prevalence of methamphetamine treatment during pregnancy in the United States. METHODS: Data were obtained from the Treatment Episode Data Set, an administrative data set that captures admissions to federally funded treatment centers in the United States. Demographic and treatment-related measures were examined among women admitted for methamphetamine use and stratified by year of admission to assess trends over time. RESULTS: From 1994 to 2006 there were 245,970 pregnant women admitted. In 1994, methamphetamine accounted for 8% of admitted pregnant women, rising to 24% by 2006. This proportion was higher than methamphetamine admissions among both nonpregnant women (12%) and men (7%). The majority of methamphetamine admissions occurred in the West (73%) among white (64%) unemployed (88%) women. Over the time of analysis, women admitted for methamphetamine treatment became sicker (measured by increasing co-occurring psychiatric disorders) and more marginalized (measured by increasing dependent-living situations and criminal justice involvement). CONCLUSION: Methamphetamine has become the primary substance compelling treatment during pregnancy. Our findings suggest a need for more effective drug and alcohol screening by clinicians who are positioned to identify and address such concerns outside the criminal justice system. LEVEL OF EVIDENCE: III.
OBJECTIVE: To estimate trends in the prevalence of methamphetamine treatment during pregnancy in the United States. METHODS: Data were obtained from the Treatment Episode Data Set, an administrative data set that captures admissions to federally funded treatment centers in the United States. Demographic and treatment-related measures were examined among women admitted for methamphetamine use and stratified by year of admission to assess trends over time. RESULTS: From 1994 to 2006 there were 245,970 pregnant women admitted. In 1994, methamphetamine accounted for 8% of admitted pregnant women, rising to 24% by 2006. This proportion was higher than methamphetamine admissions among both nonpregnant women (12%) and men (7%). The majority of methamphetamine admissions occurred in the West (73%) among white (64%) unemployed (88%) women. Over the time of analysis, women admitted for methamphetamine treatment became sicker (measured by increasing co-occurring psychiatric disorders) and more marginalized (measured by increasing dependent-living situations and criminal justice involvement). CONCLUSION:Methamphetamine has become the primary substance compelling treatment during pregnancy. Our findings suggest a need for more effective drug and alcohol screening by clinicians who are positioned to identify and address such concerns outside the criminal justice system. LEVEL OF EVIDENCE: III.
Authors: Marcela C Smid; Nicole M Stone; Laurie Baksh; Michelle P Debbink; Brett D Einerson; Michael W Varner; Adam J Gordon; Erin A S Clark Journal: Obstet Gynecol Date: 2019-06 Impact factor: 7.661
Authors: Zeina N Kiblawi; Lynne M Smith; Sabrina D Diaz; Linda L LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; Amelia Arria; Marilyn Huestis; William Haning; Arthur Strauss; Sheri DellaGrotta; Lynne M Dansereau; Charles Neal; Barry Lester Journal: Subst Abus Date: 2014 Impact factor: 3.716
Authors: Beau Abar; Linda L LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; Lynne M Smith; Amelia Arria; Marilyn Huestis; Sheri Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester Journal: Psychol Addict Behav Date: 2012-10-15